Japanese pharma group declares win in billion-dollar royalties dispute

Japan’s Mitsubishi Tanabe Pharma Corporation says it has defeated an ICC claim brought by Switzerland’s Novartis over royalties for a treatment for multiple sclerosis – a dispute understood to be worth around US$3 billion.

Unlock unlimited access to all Global Arbitration Review content